Frontlight ResearchEarly access
Taking people in United StatesPhase 4
Famotidine and Antacids for Treatment of Dyspepsia
Key facts
- Who runs it
- Stony Brook University
- Where
- Stony Brook, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 80 people, planned
- Started
- 9 Nov 2023
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Intravenous Famotidine
- Oral Maalox/ Mylanta
- Record updated
- 2 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Subject Age ≥ 18 years of age
- Patient diagnosed with dyspepsia
- Present at the ED with upper abdominal pain score of at least 3
Who cannot take part
- Inability to tolerate oral medications
- Proton pump inhibitor within 2 hours of study treatment
- Hypersensitivity to an ingredient in Maalox/ Mylanta or Famotidine
- Moderate to Severe Renal Insufficiency (precaution)
- Kidney Failure
- Pregnant or Nursing
- Verbal pain score less than 3
- Bowel Obstruction
Where in United States
- Stony Brook University HospitalStony Brook, United StatesContact: Andrea GowieTaking people
About the trial
What the trial wants to find out
The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.
The 2 groups in the trial
- Intravenous FamotidineExisting treatment, for comparison
Patients in this group will receive 20 mg of intravenous famotidine.
- Oral MaaloxExisting treatment, for comparison
Patients in the group will receive 30 ml of oral Maalox/ Mylanta.
Treatment: Oral Maalox/ Mylanta
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparing Intravenous Famotidine and Oral Antacids in the Treatment of Dyspepsia in the Emergency Department
- Record updated
- 2 June 2026